Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0021-7697(05)80960-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Patients with hidradenitis suppurativa (HS) experience a 10-year diagnosis delay, on average. Accordingly, time to diagnosis represents one of the greatest unmet needs in HS, which to date has not been adequately addressed. A general lack of awareness about HS in the medical community and a notable heterogeneity in clinical presentation, which is most often confused with cutaneous abscess (CA), forms the basis of poor disease recognition and diagnosis delay.
View Article and Find Full Text PDFMechanistic insights into ruxolitinib cream for mild hidradenitis suppurativa.
Br J Dermatol
January 2025
Division of Infection & Immunity, Cardiff University, Cardiff, UK.
Eruption of Generalized Pustular Psoriasis Following Initiation of Adalimumab for Hidradenitis Suppurativa: A Case Report.
Cureus
December 2024
Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, USA.
Rarely, tumor necrosis factor (TNF)-α inhibitors can paradoxically induce eruptions of psoriasis with generalized pustular psoriasis being among the least common presentations. We report a patient who presented with a generalized pustular eruption following adalimumab therapy for hidradenitis suppurativa (HS). The diagnosis of generalized pustular psoriasis was confirmed with a biopsy showing neutrophilic spongiosis and intraepidermal pustulosis.
View Article and Find Full Text PDFHigh-throughput proteomics identifies inflammatory proteins associated with disease severity and genetic ancestry in patients with hidradenitis suppurativa.
Br J Dermatol
January 2025
Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, MI, USA.
Background: Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition with a greater prevalence and disease burden in patients who identify as African American and those with a family history of HS, suggesting a strong genetic component to its pathogenesis.
Objective: To evaluate the relationship between plasma inflammatory protein expression, HS disease severity, and genetic ancestry in a diverse cohort of patients with Hidradenitis Suppurativa.
Methods: We performed a case-control study of patients with HS compared to age-, sex-, and ethnicity-matched healthy controls.
Potential Predictors of Biological Therapy Intensification in Moderate-To-Severe Hidradenitis Suppurativa: A Multicentre Study.
Australas J Dermatol
January 2025
Department of Dermatology, Hospital of Manises, Valencia, Spain.
Moderate-to-severe hidradenitis suppurativa (HS) is a debilitating disease that often requires biological therapy. Despite the effectiveness of approved doses, some patients experience partial or loss of response over time, leading to the need for dose intensification. This retrospective multicentre study aimed to identify predictors of biological therapy intensification in HS patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!